Single-Agent Vs Combination Regimens

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

Now Viewing

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer

EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays

EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions

EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer

Video content is prompted by the following:

Single Agent Vs Combination Regimens in Platinum-Resistant Disease

Key Discussion Points:

• Established Combination Therapies
• Bevacizumab plus chemotherapy remains standard of care in platinum-resistant setting

• Weekly paclitaxel combined with bevacizumab increases response rates from 30% to 50%

• Many patients cannot receive bevacizumab due to contraindications (hypertension, bowel obstruction, extensive intestinal disease)
• Emerging Combination Approaches
• Ongoing trials examining new combinations (olvimulogene nanivacirepvec [olvi-vec] with chemotherapy, relacorilant, and abraxane)

• Bevacizumab with mirvetuximab showing promise in specific clinical situations

• Limited true synergistic combinations identified to date in clinical practice
• PICCOLO Trial Data
• Single-arm trial of approximately 80 patients with folate receptor alpha–high recurrent disease

• 52% response rate with mirvetuximab in platinum-sensitive patients after ≥2 lines of platinum

• Duration of response just under 8 months with approximately 50% having previously progressed on PARP inhibitors

Notable Insights:

1. “PICCOLO is our really first successful look at...replacing platinum with another agent. We’ve tried to do it in the past with a study called MITO8, which was pre-PARP...but it was ahead of its time.”
2. “Unless something’s truly synergistic—which, newsflash—nothing is. Synergy is not a thing clinically. It’s a thing in mice.”
3. “Sometimes you’re using combos, and you’re just using up medications together that you could sequence with less toxicity and probably more benefit to the patient.”